Injection drug use and patterns of highly active antiretroviral therapy use: An analysis of ALIVE, WIHS, and MACS cohorts

AIDS Research and Therapy

Volumn 4, Issue , 2007, Pages

  Morris, John D ^a   Golub, Elizabeth T ^a   Mehta, Shruti H ^a   Jacobson, Lisa P ^a   Gange, Stephen J ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; TENOFOVIR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ETHNIC GROUP; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCOME; INFECTION CONTROL; INTRAVENOUS DRUG ABUSE; LONG TERM CARE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RISK FACTOR;

EID: 34250819835     PISSN: 17426405     EISSN: None     Source Type: Journal    
DOI: 10.1186/1742-6405-4-12     Document Type: Article

References (28)

1. Palella FJ Jr Delaney KM Moorman AC Loveless MO Fuhrer J Satten GA Aschman DJ Holmberg SD Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection N Engl J Med 1998 338 853-860 10.1056/NEJM199803263381301 9516219
2. Gange SJ Barrón Y Greenblatt RM Anastos K Minkoff H Young M Kovacs A Cohen M Meyer WA 3rd Muñoz A Effectiveness of highly active antiretroviral therapy among HIV-1 infected women J Epidemiol Community Health 2002 56 153-9 10.1136/jech.56.2.153 11812817
3. Friedland GH HIV medication adherence. The intersection of biomedical, behavioral, and social science research and clinical practice J Acquir Immune Defic Syndr 2006 Suppl 1 3-9
4. Chesney MA The elusive gold standard. Future perspectivesfor HIV adherence assessment and intervention J Acquir Immune Defic Syndr 2006 Suppl 1 149-55
5. Mehta S Moore RD Graham NMH Potential factors affecting adherence with HIV therapy AIDS 1997 11 1665-1670 10.1097/00002030-199714000-00002 9386800
6. Libman H Makadon HJ Antiretroviral Therapy HIV Philadelphia: American College of Physicians Hurtado RM, Sax PE 2003
7. Deeks SG Wrin T Liegler T Hoh R Hayden M Barbour JD Hellmann NS Petropoulos CJ McCune JM Hellerstein MK Grant RM Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia N Engl J Med 2001 344 520-522 10.1056/NEJM200102153440702 11172196
8. Ahdieh Grant L Silverberg MJ Palacio H Minkoff H Anastos K Young MA Nowicki M Kovacs A Cohen M Muñoz A Discontinuation of potent antiretroviral therapy: Predictive value of and impact on CD4 cell counts and HIV RNA levels AIDS 2001 15 2102-2108 10.1097/ 00002030-200111090-00005
9. Barrón Y Cole SR Greenblatt RM Cohen MH Anastos K DeHovitz JA Delapenha R Gange SJ Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy AIDS 2004 18 1579-1584 10.1097/01.aids.0000131359.37210.1f 15238776
10. Van Roon EN Verzijl JM Juttmann JR Lenderink AW Blans MJ Egberts ACG Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants J Acquir Immun Defic Human Retrovir 1999 20 290-294
11. d'Arminio Monforte A Lepri AC Rezza G Pezzotti P Antinori A Phillips AN Angarano G Colangeli V De Luca A Ippolito G Caggese L Soscia F Filice G Gritti F Narciso P Tirelli U Moroni M Insights into the reasons for discontinuation of the first active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients AIDS 2000 14 499-507 10.1097/00002030-200003310-00005 10780712
12. Mocroft A Youle M Moore A Sabin CA Madge S Lepri AC Tyrer M Chaloner C Wilson D Loveday C Johnson MA Phillips AN Reasons for modification and discontinuation of antiretrovirals: Results from a single treatment centre AIDS 2001 15 185-194 10.1097/00002030-200101260-00007 11216926
13. Palella FJ Chmiel JS Moorman AC Homberg SD Durability and predictors of success of highly active antiretroviral therapy for ambulatory HIV-infected patients AIDS 2002 16 1617-1626 10.1097/ 00002030-200208160-00007 12172083
14. Chen RY Westfall AO Mugavero MJ Cloud GA Raper JL Chatham AG Acosta EP Taylor KH Carter J Saag MS Duration of highly active antiretroviral therapy regimens Clin Infect Dis 2003 37 714-722 10.1086/377271 12942406
15. Kirstein LM Greenblatt RM Anastos K Levine A French AL Minkoff H Silver S Gange SJ Prevalence and correlates of highly active antiretroviral therapy switching in the Women's Interagency HIV Study J Acquir Immune Defic Syndr 2002 29 495-503 11981366
16. Ahdieh-Grant L Tarwater PM Schneider MF Anastos K Cohen M Khalsa A Minkoff H Young M Greenblatt RM Factors and temporal trends associated with highly active antiretroviral therapy discontinuation in the Women's Interagency HIV Study J Acquir Immune Defic Syndr 2005 38 500-503 10.1097/01.qai.0000138160.91568.19 15764968
17. Li X Margolick JB Conover CS Badri S Riddler SA Witt MD Jacobson LP Interruption and discontinuation of highly active antiretroviral therapy in the Multicenter AIDS Cohort Study J Acquir Immune Defic Syndr 2005 38 320-328 15735452
18. DHHS/Henry J Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents October 2004 revision http://aidsinfo.nih.gov/
19. Vlahov D Anthony JC Munoz A Margolick J Nelson KE Celentano DD Solomon L Polk BF The ALIVE study: A longitudinal study of HIV-1 infection in intravenous drug users: Description of methods J Drug Issues 1991 21 759-776
20. Barkan SE Melnick SL Preston-Martin S Weber K Kalish LA Miotti P Young M Greenblatt R Sacks H Feldman J The Women's Interagency HIV Study Epidemiology 1998 117-125 9504278
21. Kaslow RA Ostrow DG Detels R Phair JP Polk BF Rinaldo CR Jr The Multicenter AIDS Cohort Study: Rationale, organization, and selected characteristics of the participants Am J Epidemiol 1987 126 310-318 3300281
22. Zeger SL Liang KY Longitudinal data analysis for discrete and continuous outcomes Biometrics 1986 42 121-130 10.2307/2531248 3719049
23. Singer JD Willett JB Applied Longitudinal Data Analysis New York: Oxford University Press 2003
24. Bini T Testa L Chiesa E Adorni F Abeli C Castelnuovo B Melzi S Sollima S Bongiovanni M d'Arminio Monforte A Outcome of a second-line protease inhibitor-containing regimen in patients failing or intolerant of a first highly active antiretroviral therapy J Acquir Immune Defic Syndr 2000 24 115-122 10935686
25. Gallant JE Initial therapy of HIV infection Journ Clin Virol 2002 25 317-333 10.1016/S1386-6532(02)00024-0
26. Pach A Cerbone FG Gerstein DR A qualitative investigation of antiretroviral therapy among injection drug users AIDS Behav 2003 7 87-100 10.1023/A:1022517608578 14534393
27. Silverberg MJ Wegner SA Milazzo MJ McKaig RG Williams CF Agan BK Armstrong AW Gange SJ Hawkes C O'Connell RJ Ahuja SK Dolan MJ Effectiveness of highly-active antiretroviral therapy by race/ethnicity AIDS 2006 13;20 1531-8
28. Lau B Gange SJ Moore RD The clinical cohort study:ePidemiologic issues AIDS Research and Human Retroviruses in press.